Croda International acquired Brenntag Biosector for €72m.

Croda International, a British speciality chemicals company, acquired Brenntag Biosector from Brenntag Nordic, the global market leader in chemical distribution, for €72m. Biosector is a specialist in the manufacture and supply of adjuvants serving the human and veterinary vaccine market. Steve Foots, Chief Executive of Croda, commented: "Biosector is a rare asset, in a high value, fast growing sector of the global pharmaceutical market. With an experienced high-quality team, Biosector brings world-class protected technologies and industry-leading manufacturing facilities. Furthermore, the strong cultural alignment between Biosector and Croda enhances our highly technical-based sales approach and emphasis on value over volume. The opportunity to quickly build upon Biosector's impressive track record to date is enormously exciting and we look forward to welcoming the team to Croda."